Dissolution testing in the modern world
Historically, dissolution testing has been used primarily as a quality control (QC) test for solid oral drug products1. Indeed, it is the only QC test which provides a measure of the quantitative release rate of the drug from the pharmaceutical product. More recently, the test has been proposed in lieu of bioequivalence testing2,3,4. However, can the same dissolution test have enough robustness (as per 5) to be used as a routine QC tool, whilst simultaneously being sensitive enough to be truly bio-predictive? This article will explore this conundrum.
A recent United States Food and Drug Administration (FDA) guidance6 describes how sponsors can apply for waivers in lieu of in vivo bioavailability and bioequivalence testing based on a combination of the biopharmaceutics classification system (BCS) and in vitro dissolution testing. BCS classifies compounds into four categories based on their solubility and permeability characteristics. Highly soluble compounds are categorised as BCS class 1 (highly permeable) or BCS class 3 (poorly permeable) and poorly soluble compounds are classified as BCS class 2 (highly permeable) or BCS class 4 (poorly permeable).
The objectives of the guidance was twofold: to provide a strategy to identify those clinical bioequivalence tests which may not be required and secondly, to recommend where dissolution testing can be used to replace bioequivalence testing, advising on methods for solubility, dissolution and permeability to aid in this classification. Some immediate-release products can be classified as having very rapid dissolution and in some instances the BCS classification can be used as a justification for a subsequent bio-waiver. Where the in vivo dissolution of an immediate-release product is very fast with respect to gastric emptying, and the drug solubility is high, then drug absorption is typically not affected by dissolution rate. Similarly, when the gastrointestinal tract transit times are rapid it is not always necessary to perform in vivo bioavailability or bioequivalence studies for BCS class 1 and 3 drugs6 .
To support a bio-waiver, the drug substance must be shown to be both highly soluble and permeable (BCS class 1) and it must be rapidlydissolving, i.e., ≥ 85% of the analyte must dissolve in ≤ 15 minutes under the defined conditions and the excipients present in the drug product must not impact on the permeability and subsequent rate of absorption of the drug. For BCS class 3 products, the drug substance needs to be highly soluble and rapidly dissolve, and the test product formulation is required to be quantitatively and qualitatively similar to the reference product. There are some instances where the FDA has stated that bio-waivers are not appropriate, i.e., narrow therapeutic range drugs such as warfarin sodium and products designed for absorption in the oral cavity6 .
The rest of this article is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- bi-monthly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!